Physician profile
Joel E Nachimson
NPI 1922040633
$2,301.49
in general payments reported to CMS, 2019-2025
28 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.80 · 2020: $81.63 · 2021: $230 · 2022: $284 · 2023: $811 · 2024: $608 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $542.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $230.87 | 2022-2025 | |
| Novo Nordisk INC | $163.41 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $154.56 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Ucb, INC. | $146.58 | 2023-2024 | Rystiggo |
| Glaxosmithkline, LLC. | $108.60 | 2023-2025 | Shingrix, Arexvy |
| Amgen INC. | $95.19 | 2019-2021 | |
| Inspire Medical Systems, INC. | $89.18 | 2023 | Inspire |
| Avion Pharmaceuticals | $87.88 | 2022-2023 | Dhivy |
| Abbvie INC. | $82.68 | 2022-2025 | |
| Astellas Pharma US INC | $78.87 | 2021-2025 | Veozah |
| Sk Life Science, INC. | $60.45 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $55.44 | 2019-2024 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $55.42 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.34 | 2023-2024 | Xifaxan, Trulance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $40.68 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Horizon Therapeutics Plc | $33.10 | 2022 | |
| Exact Sciences Corporation | $33.02 | 2024-2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $28.76 | 2023 | Ingrezza |
| Mauna Kea Technologies, INC. | $25.30 | 2021 | |
| Eisai INC. | $24.80 | 2024 | |
| Boston Scientific Corporation | $24.01 | 2020 | |
| Supernus Pharmaceuticals, INC. | $19.13 | 2022 | Xyosted, Tlando |
| Life Molecular Imaging LTD | $18.11 | 2022 | |
| Halozyme INC | $15.43 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.87 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Nachimson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.